Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, et al. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Eur J Obstet Gynecol Reprod Biol. 2019;236:214–23.

Article  CAS  PubMed  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49.

Article  PubMed  Google Scholar 

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. https://doi.org/10.1056/NEJMoa0908806. 2010. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. Available from: https://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa0908806?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov. Cited 2019 Nov 22

Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialicles.

Colombo N, Sessa C, Bois A du, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2019 02;

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Cancer Netw JNCCN. 2019;17(8):896–909.

Article  CAS  PubMed  Google Scholar 

Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2020 Oct 7;

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416–28.

Article  CAS  PubMed  Google Scholar 

Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2011;21(4):750–5.

Article  Google Scholar 

Bendifallah S, Body G, Daraï E, Ouldamer L. Pertinence des marqueurs tumoraux, scores (cliniques et biologiques) et algorithmes à visée diagnostique et pronostique devant une masse ovarienne suspecte d’un cancer épithélial. Article rédigé sur la base de la recommandation nationale de bonnes pratiques cliniques en cancérologie intitulée « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l’égide du CNGOF et labellisée par l’INCa. Gynécologie Obstétrique Fertil Sénologie. 2019;47(2):134–54.

Article  CAS  Google Scholar 

You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, et al. CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2020 Mar 24;

Lee YJ, Lee IH, Kim YJ, Chung YS, Lee JY, Nam EJ, et al. Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy. PLoS ONE. 2018;13(9): e0203366.

Article  PubMed  PubMed Central  Google Scholar 

Baek MH, Lee SW, Park JY, Rhim CC, Kim DY, Suh DS, et al. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2017;27(3):420–9.

Article  Google Scholar 

Pelissier A, Roulot A, Guéry B, Bonneau C, Bellet D, Rouzier R. Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer. J Ovarian Res. 2016;9(1):61.

Article  PubMed  PubMed Central  Google Scholar 

Pelissier A, Bonneau C, Chéreau E, de La Motte RT, Fourchotte V, Daraï E, et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2014;135(3):542–6.

Article  CAS  PubMed  Google Scholar 

Zeng J, Yin J, Song X, Jin Y, Li Y, Pan L. Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma. J Cancer. 2016;7(15):2327–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vallius T, Hynninen J, Auranen A, Carpén O, Matomäki J, Oksa S, et al. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35(12):12389–95.

Article  CAS  Google Scholar 

Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125(2):362–6.

Article  CAS  PubMed  Google Scholar 

Le T, Faught W, Hopkins L, Fung-Kee-Fung M. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC. 2008;30(8):665–70.

Article  Google Scholar 

Karamouza E, Glasspool RM, Kelly C, Lewsley LA, Carty K, Kristensen GB, et al. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. Cancers. 2023;15(6):1823.

Article  CAS  PubMed  PubMed Central  Google Scholar 

You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, et al. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecol Oncol. 2013;130(2):289–94.

Article  CAS  PubMed  Google Scholar 

Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2014;124(1):1–5.

Article  Google Scholar 

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

Article  CAS  PubMed  Google Scholar 

Colomban O, Clamp A, Cook A, McNeish IA, You B. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial. JCO Clin Cancer Inform. 2023;7: e2200188.

Article  PubMed  PubMed Central  Google Scholar 

Lauby A, Colomban O, Corbaux P, Peron J, Van Wagensveld L, Gertych W, et al. The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review. Cancers. 2021;14(1):98.

Article  PubMed  PubMed Central  Google Scholar 

Bouvarel B, Colomban O, Frenel JS, Loaec C, Bourgin C, Berton D, et al. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2024 Jan 19;ijgc–2023–004872.

You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, et al. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2022. Available from:  Jul 22. https://ascopubs.org/doi/https://doi.org/10.1200/JCO.22.00430. Cited 2024 Mar 18.

Santoro A, Angelico G, Piermattei A, Inzani F, Valente M, Arciuolo D, et al. Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease. Front Oncol. 2019 Aug 19;9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709655/. Cited 2020 Oct 27 .

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019;154(2):441–8.

Article  PubMed  Google Scholar 

Marchetti C, Ergasti R, Capomacchia FM, Giannarelli D, Sassu CM, Zannoni GF, et al. The role of Chemotherapy Response Score (CRS) in the decision making process for patients with advanced high grade serous ovarian cancer undergoing neoadjuvant chemotherapy. J Clin Oncol. 2023;41(16_suppl):5591–5591.

Article  Google Scholar 

Bogani G, Matteucci L, Tamberi S, Ditto A, Sabatucci I, Murgia F, et al. RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy. Eur J Obstet Gynecol Reprod Biol. 2019;237:93–9.

Article  PubMed  Google Scholar 

Vigneron N, Vernon M, Meryet-Figuière M, Lambert B, Briand M, Louis MH, et al. Predictive Relevance of Circulating miR-622 in Patients with Newly Diagnosed and Recurrent High-Grade Serous Ovarian Carcinoma. Clin Chem. 2020;66(2):352–62.

Article  PubMed  Google Scholar 

Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, et al. A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(18):4482–93.

Article  CAS  Google Scholar 

Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(3):764–75.

Article  CAS  Google Scholar 

Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16(8):2315–20.

Article  PubMed  Google Scholar